Aussie CDMO AcuraBio acquired by Ampersand and Dr Haifer

AcuraBio (formerly Luina Bio), an Australian biopharma contract development and manufacturing organization (CDMO), has been acquired by biotech investor Dr Glenn Haifer and Ampersand Capital Partners, a USA-based private equity firm. Financial terms of the transaction were not revealed.

With more than two decades of experience, AcuraBio is a globally focussed organization bringing innovative therapeutics to market for customers in the biotech, pharmaceutical, and animal health industries. AcuraBio provides recombinant proteins and vaccines, and complex live biotherapeutic products to customers on the leading edge in emerging therapeutics.

AcuraBio planning to increase production facility capacity

The rebranding of the company signifies an innovative new growth phase for AcuraBio. As part of the transaction, Dr Haifer and Ampersand are bringing significant investment to the company, with a focus on expanding the organization to better serve customers. To fuel additional growth, AcuraBio is planning to increase production facility capacity, and is actively evaluating expansion into new service offerings and technological capabilities.

Dr Haifer brings a wealth of experience to AcuraBio, as the former company chairman and investor behind Australian biotech successes such as Agilex Biolabs and Avance Clinical.